Search for:
Search for:
Healthcare Professionals
Publications
News
EspaƱol
Contact
Magazine
Radio
Donate
Get Educated
What is MS?
A chronic neurological disorder that affects the central nervous system, comprised of the brain...
More Details
Educational Materials
Common Questions
Lending Library
Symptoms
Treatment Options
Additional Resources
Research
MS Awareness Month
Get Help
Health & Wellness Program
Get educational materials and referrals, as well as the opportunity to participate in various...
Learn More
Grants & Programs
Awareness Campaigns
Support Groups
Events
Lending Library
Additional Resources
Get Involved
MS Awareness Month
An annual, nationwide campaign with goals to promote an understanding of MS, and to assist those...
Learn More
Advocacy
Buy from Partners
Volunteer
Businesses
MS Research Trials
Outreach
Awareness Campaigns
Host an Event
Events
Test Flyout
lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem...
Learn More
Events Calendar
Health & Wellness
Fundraisers
Support
Web & Teleconferences
MS Education
Host an Event
About Us
Programs & Grants
More Details
Overview
Press Room
Leadership
Financial Statements
Our Mission
Careers at MS Focus
Affiliations
News & Features
When Care(giving) Meet...
Live, educational event for the community around Greenville, SC.
/Events/MSF-Events/2019/One-Time-Events/When-Care(giving)-Meets-Love-(2)
Healthcare Assistance ...
The MS Focus Healthcare Assistance Grant assists uninsured individuals with the cost of visiting...
/Get-Help/MSF-Programs-Grants/Healthcare-Assistance-Grant
Shop
Privacy
Terms of Use
Site Map
FDA approves new generic for Copaxone
October 06, 2017
The U.S. Food and Drug Administration has approved Mylan's Abbreviated New Drug Applications for glatiramer acetate as substitutable generic versions of Teva's Copaxone, which are indicated for the treatment of patients with relapsing forms of multiple sclerosis. Mylan will begin shipping imminently.
The FDA approved Mylan's glatiramer acetate injection 40 mg/mL for 3-times-a-week injection and 20 mg/mL for once-daily injection as therapeutic AP-rated equivalents to Copaxone® 40 mg/mL and Copaxone® 20 mg/mL, respectively, meaning if they are substituted for their branded counterpart they can be expected to have the same clinical effect and safety profile. As part of its application, Mylan submitted rigorous side-by-side analyses, including characterization data, which demonstrated that Mylan's glatiramer acetate injection 20 mg/mL and 40 mg/mL have the same active ingredient, dosage form, route of administration and strength as their branded counterpart. Mylan's glatiramer acetate injection 20 mg/mL and 40 mg/mL are available by prescription only.
In addition, Mylan is introducing Mylan MS Advocate, a comprehensive patient support service program to help patients get started on and stay on track with their physician's treatment plan for either dose strength of Mylan's Glatiramer Acetate Injection. All patients prescribed and taking Mylan's Glatiramer Acetate Injection 3-times-a-week 40 mg/mL or once-daily 20 mg/mL are eligible to enroll in the program which includes an interactive mobile app, in-home injection training, a 24/7 patient support center, co-pay assistance for eligible patients and ongoing support from an MS-experienced nurse.
For more information call 844-MYLAN MS (695-2667) or visit GlatiramerAcetate.com.
MS Focus Lending Library
Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more
Study uncovers potential risks of common MS treatment
Study finds an increased risk of events such as stroke, migraine, and depression, and abnormalities in the blood with taking beta interferon for MS.
Learn more